Article: Nicotinamide Riboside Supplementation Raises NAD+ and Lowers Alzheimer's-Associated Biomarkers: Clinical Findings

Dec 14, 2022 Clinical Neurological Health

Nicotinamide Riboside Supplementation Raises NAD+ and Lowers Alzheimer's-Associated Biomarkers: Clinical Findings

Objectives

To evaluate if NR could augment neuronal NAD+ levels and impact markers of neurodegeneration and insulin-signaling in plasma-derived human neuronal extracellular vesicles (NEVs).

Journal

Aging Cell

Key Outcomes

NR supplementation significantly increased NAD+ in plasma derived human neuronal extracellular vesicles (NEVs), suggesting an increase in neuronal NAD+ levels.
In NEVs, NR also decreased levels of Aβ42, an Alzheimer's disease biomarker, as well as biomarkers pJNK and pERK1/2, which are involved in insulin resistance and neuroinflammatory pathways.

Duration

6 weeks

Dose

1000 mg

Study Design

Randomized, double-blind, placebo-controlled, crossover study in 22 healthy, middle-aged and older men and women

See Published Study

Ataxia Telangiectasia

Early Nicotinamide Riboside Supplementation Shows Promise in an Individual with Ataxia Telangiectasia: Case Report

Objective To investigate the effects of NR supplementation in a 3.5-year-old male child with ataxia and recurrent bacterial infections. This was a case study of one individual. Journal Neuropediatr...

Clinical

Nicotinamide Riboside Supplementation Increases Muscle Mitochondrial Biogenesis & Gut Health: Clinical Findings

Objectives To investigate the effects of long-term NR supplementation on mitochondrial biogenesis and metabolic health in humans. Journal Science Advances Key Outcomes In the BMI-discordant twin...